Abstract
Executive Summary
"Analytical Tool: Analysis of Colorectal Cancer R&D - The Complete Guide"
offers a unique tool for analysing the vast amount of strategic possibilities
that have emerged in colorectal cancer (CRC) R&D and business development. It
is at the same time a map of the research and development, a history of the
achievements up to date, and a guide pointing out the directions of the future.
This tool provides you with an immense amount of information structured and
analysed to assist you in your work. In-depth analysis is found in a 180+
pages report with more than 100 figures, tables and boxes, which deals with
the current therapy strategies employed and opportunities for increased
pharmaceutical intervention, in the context of the present competitive
landscape for CRC.
Additionally, BioSeeker also includes a CD-ROM searchable database in this
tool, which is up to date and reflects the most recent advances in the field
of CRC development. This database will let you go back to source data for
in-depth information and lets you present research and development in tables
and graphs suited for your own specific purposes.
This tool includes:
- Information and competitive landscape analysis on more than 200 companies
active in CRC R&D
- Information on more than 200 CRC drug projects
- Progress analysis on more than 70 CRC Drugs
- A multitude of tables and graphs illustrating the most important relations
between types of therapy, effects and mechanisms
- Advanced analysis of general and specific trends in the pipeline
- Possibility of performing advanced searches suited to your individual needs
This tool will assist you in:
- Tracking cutting edge companies, therapies and new technologies
- Rapid identification of partners & competitors
- Laying down a comprehensive framework for further analysis of the field
- Identifying emerging CRC products & key areas of pharmaceutical R&D
Example of candidate drugs included:
The complete number of candidate drugs in R&D for CRC are more than 200 and we
have listed some of them below:
AMG 706, batabulin, becatecarin, bevacizumab, canvaxin, DRF 1042, EP 2101,
folic acid analogue, ADVENTRX, HSPPC 96, HyCAMP, IB-MECA, Maxy 1200, MS 275,
NB 1011, NV 1020, oblimersen, panitumumab, patupilone, PD 0325901, picoplatin,
SGN 15, tetrathiomolybdate, triacetyluridine, troVax, vatalanib etc
Example of companies included:
BioSeeker has identified more than 200 companies within the sphere of CRC and
we have listed some of the important players within this field below:
Acera Biosciences, ADVENTRX, Agensys, Amgen, AnorMED, Antigenics, Attenuon,
AVI BioPharma, Can-Fite, Cell Therapeutics, Corixa, Cosmo Bioscience, Dr
Reddys, Elan, Epimmune, GemVax, Genencor, Genentech, GenVec, GlaxoSmithKline,
Hoffmann La Roche, Igeneon, Immunomedics, Inex, J&J, MediGene, MedImmune,
MediPharm, Millennium, Novartis, Novozymes, Onyvax, OXiGENE, Pfizer,
Phytopharm, Prolexys, Scancell, Schering AG, Seattle Genetics, Serono,
Structural GenomiX, Supergen, Taiho, Threshold, Titan Pharmaceuticals,
Transgene, Wyeth, Xenova etc.
System Requirements
- - AMD-Athlon/Pentium II PC
- - Windows 98/NT4/2000/ME/XP/VISTA
- - 8x-speed CD Rom drive
- - SVGA 16 bit display. (32 bit recommended)
- - 32 MB of available RAM (128 MB recommended)
- - Internet access (for related internet resources)
View Cart
